

Balaxi Pharmaceuticals Limited

November 15,2024

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Intimation of reaffirmation of Credit Rating and revision in outlook

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that vide a communication received on 15.11.2024 (at 12.38 PM IST), CRISIL Ratings Limited has reaffirmed its rating at 'CRISIL BBB+' on the long-term bank facilities of the Company while revising the outlook from negative to stable.

Name of the Company	Credit Rating Agency	Type of Credit Rating	Prior Rating	Revised Rating
Balaxi Pharmaceuticals Limited	CRISIL Ratings Limited	Long Term	CRISIL BBB+/Negative(Outlook revised from 'Stable'; Rating reaffirmed)	CRISIL BBB+/STABLE (Outlook revised from 'Negative'; Rating Reaffirmed)

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,
For **Balaxi Pharmaceuticals Limited**

Ashish Maheshwari
Managing Director
DIN:01575984

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in